Goldman Sachs Alternatives led a $132m Series B round in Alterome Therapeutics.

Goldman Sachs Alternatives, a private equity firm, led a $132m Series B round in Alterome Therapeutics, a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, with participation from Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. “We are pleased with a financing of this magnitude that enables Alterome to advance multiple programs into the clinic within the next 12 months. The precision oncology field has arrived at a special moment with the exciting evolution of both drug discovery and precision medicine. A unique integration of structure-guided drug discovery with deep translational biology is facilitating the development of novel therapies that address previously inaccessible proteins. We are thrilled to have the support of this visionary group of new and existing investors, who share our enthusiasm to face the challenge of targeting well-known cancer-causing mutations deemed undruggable for the previous 20 years,” Eric Murphy, Alterome Therapeutics co-founder and CEO.